ISSN : 0975-4423
EISSN : 0975-914X
Hariprasad O.1*, Gopinath V.P.2, Navya A.3, Yugandhar V.G.4, Sarma P.V.G.K5
1Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences & SVIMS University, Tirupati, Andhra Pradesh, India
2Department of Animal Biotechnology, Madras Veterinary College, Chennai, India.
3Department of Applied Microbiology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, Andhra Pradesh, India
4Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences & SVIMS University, Tirupati, Andhra Pradesh, India.
5Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences & SVIMS University, Tirupati, Andhra Pradesh, India
* Corresponding Author : hari.osuru@gmail.com
Received : - Accepted : - Published : 21-12-2010
Volume : 2 Issue : 2 Pages : 17 - 19
Int J Drug Discov 2.2 (2010):17-19
DOI : http://dx.doi.org/10.9735/0975-4423.2.2.17-19
Keywords : mmune response, Sero conversation, Antigenicity, Nanoparticles and
Vaccination.
Conflict of Interest : None declared
Particulate vaccines made a remarkable break through in the vaccines and drug delivery systems. With their fine small structure they can pass through the cellular systems and can trigger the type I and type II immune systems, which aid in the better immune response. The sero conversation and the longevity of the particulate vaccines are found to be better than the regular conventional vaccines. The development of recombinant vaccines and sub unit vaccines having safer side in vaccination could not elicit stronger immune response, because of their partial antigenicity. In such cases when coupled with nanoparticles triggers better immune response. Recombinant Tetanus toxoid and Diphtheria toxoid when coupled with nanoparticles showed significant TH1 and TH2 immune responses. Particulate vaccines can be used in mucosal, nasal, ocular or transcutaneous modes for vaccination.
[1] Noemi Csaba, Marcos Garcia-
Fuentes and Maria Jose
Alonso. (2009) Advanced
Drug Delivery Reviews, 61,
140-157.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[2] Jayanth Panyama and Vinod
L. (2003) Advanced Drug
Delivery Reviews, 55, 329-
347.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[3] Van der Lubben I.M., Verhoef
J.C., Borchard G. and
Junginger H.E. (2001)
AdvancedDrug Delivery
Reviews, 52,139-144
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[4] Laura J. Peek, Russell
Middaugh C. and Cory
Berkland (2008) Advanced
DrugDelivery Reviews, 60,
915-928
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[5] Samantha Jilek, Hans P.
Merkle and Elke Walter.
(2005) Advanced Drug
Delivery Reviews, 57, 377-
390
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[6] Omid C. Farokhzad and
Robert Langer (2006)
Advanced Drug Delivery
Reviews, 58, 1456-1459
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[7] Yoshiaki Kawashima (2001)
Advanced Drug Delivery
Reviews, 47, 1-2.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[8] Tazio Storni; Thomas M. K.,
Gabriela Senti and Pal
Johansen. (2005) Advanced DrugDelivery Reviews, 57,
333-355.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[9] Dang J.M. and Leong K. W.
(2006) Advanced Drug
Delivery Reviews, 58, 487-
499.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[10] Fiona A. S., Darren R.,
Benjamin C., Emma C.,
James H., Padma M.,
Manomohan S., Derek T.
O'Hagan, Virginie P., Jurg T.,
Luke A. J. O'Neill. and Ed C. Lavelle. (2009) Proceedings of
the National Academy of
Sciences of the United States
of America, 106(3), 870-875
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[11] Angie westwood, Gareth D.
Healey, Diane williamson E.
and Jim Eyles E. (2005)
Vaccine, 23, 3857-3863.
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus
[12] Manish Diwan; Mohsen
Tafaghodi and John Samuel.
(2002) Journal of Controlled
Release, 85, 247-262
» CrossRef » Google Scholar » PubMed » DOAJ » CAS » Scopus